Home

Arcturus Therapeutics Holdings Inc (ARCT)

19.21
+0.00 (0.00%)
NASDAQ · Last Trade: Aug 14th, 5:28 AM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors
12 Health Care Stocks Moving In Wednesday's Intraday Sessionbenzinga.com
Via Benzinga · August 13, 2025
Intapp Posts Better-Than-Expected Earnings, Joins Sapiens International, Arcturus Therapeutics, Gildan Activewear And Other Big Stocks Moving Higher On Wednesdaybenzinga.com
Via Benzinga · August 13, 2025
Mercury Systems Posts Better-Than-Expected Earnings, Joins Green Dot, Arcturus Therapeutics And Other Big Stocks Moving Higher On Tuesdaybenzinga.com
Via Benzinga · August 12, 2025
Earnings Scheduled For May 12, 2025benzinga.com
Via Benzinga · May 12, 2025
Beyond The Numbers: 8 Analysts Discuss Arcturus Therapeutics Stockbenzinga.com
Via Benzinga · March 7, 2025
Breaking Down Arcturus Therapeutics: 5 Analysts Share Their Viewsbenzinga.com
Via Benzinga · February 14, 2025
Demystifying Arcturus Therapeutics: Insights From 5 Analyst Reviewsbenzinga.com
Via Benzinga · January 28, 2025
12 Health Care Stocks Moving In Tuesday's Intraday Sessionbenzinga.com
Via Benzinga · August 12, 2025
Top movers in Tuesday's sessionchartmill.com
Intrigued by the market activity in the middle of the day on Tuesday? Uncover the key winners and losers of today's session in our insightful analysis.
Via Chartmill · August 12, 2025
Arcturus Therapeutics Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)benzinga.com
Via Benzinga · August 12, 2025
Expert Outlook: Arcturus Therapeutics Through The Eyes Of 5 Analystsbenzinga.com
Via Benzinga · July 2, 2025
Unveiling 3 Analyst Insights On Arcturus Therapeuticsbenzinga.com
Via Benzinga · October 1, 2024
Earnings Scheduled For August 11, 2025benzinga.com
Via Benzinga · August 11, 2025
Which stocks are moving before the opening bell on Tuesday?chartmill.com
Let's have a look at what is happening on the US markets before the opening bell on Tuesday. Below you can find the top gainers and losers in today's pre-market session.
Via Chartmill · May 13, 2025
Demystifying Arcturus Therapeutics: Insights From 7 Analyst Reviewsbenzinga.com
Via Benzinga · May 13, 2025
12 Health Care Stocks Moving In Tuesday's Pre-Market Sessionbenzinga.com
Via Benzinga · May 13, 2025
Which stocks are moving after the closing bell on Monday?chartmill.com
The US market regular session of Monday is over, let's have a look at the top gainers and losers in the after hours session today.
Via Chartmill · May 12, 2025
Earnings Scheduled For March 6, 2025benzinga.com
Via Benzinga · March 6, 2025
Arcturus Therapeutics/CSL Partnered COVID-19 Vaccine Surpasses Pfizer's Comirnaty Shot, Even At Lower Dosesbenzinga.com
CSL and Arcturus Therapeutics report that their sa-mRNA COVID-19 vaccine, ARCT-154, delivered superior immunogenicity compared to Pfizer's Comirnaty in a Phase 3 study, persisting for one year and at a lower dose.
Via Benzinga · September 30, 2024
ARCT Stock Earnings: Arcturus Therapeutics Beats EPS, Beats Revenue for Q2 2024investorplace.com
ARCT stock results show that Arcturus Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via InvestorPlace · August 5, 2024
Cathie Wood-Led Ark Invest Dumps $4.3M Worth Of Nvidia Shares Amid Rebound — Swoops Into Buy Stock Of This Netflix Rivalbenzinga.com
Via Benzinga · June 25, 2024
Cathie Wood-Led Ark Invest Sells $1.5M Worth Of Robinhood Shares Amid Muted Bitcoin Market — Also Dumps Zoom Stock Worth $3.3Mbenzinga.com
Ark Invest, led by Cathie Wood, made significant trades on Wednesday involving Robinhood Markets Inc (NASDAQ:HOOD) and Zoom Video Communications Inc (NASDAQ:ZM).
Via Benzinga · June 12, 2024
Cathie Wood-Lead Ark Invest Dumps $7.6M Worth Of Robinhood Shares Amid GameStop Buzz, Bitcoin Choppinessbenzinga.com
On Monday, Cathie Wood-led Ark Invest made a significant move by reducing its holdings in Robinhood Markets Inc (NASDAQ:HOOD). This decision came amidst a period of market fluctuations and followed a recent trend of the investment firm adjusting its portfolio.
Via Benzinga · June 10, 2024
Arcturus' Inhaled mRNA Therapeutic In Cystic Fibrosis Study Highlights Potential Amid Competitive Landscape: Analystbenzinga.com
Arcturus Therapeutics shared Phase 1 and Phase 1b trial results for ARCT-032, an inhaled mRNA therapeutic for cystic fibrosis, showing FEV1 improvements and safety .
Via Benzinga · June 7, 2024
12 Health Care Stocks Moving In Friday's Intraday Sessionbenzinga.com
Via Benzinga · June 7, 2024